CT-P59·63 / Celltrion - LARVOL DELTA

Celltrion In the third quarter of this year, South African mutant COVID-19 treatment enters clinical trial [Google translation] (Maeil) - "Celltrion [068270] announced a plan to enter a clinical trial for a treatment for a mutated Corona 19 virus originating in South Africa with its new 32nd antibody 'CT-P63' in the third quarter of this year. Celltrion's Dr. Dong-gyun Ryu announced the neutralizing effect of 'Rekkirona'...on the mutation of Corona 19 at '2021 Bio Korea'...'Rekkirona maintained neutralizing ability against the British mutant virus and showed a decrease in neutralizing ability against the South African mutant,'...'CT-P63 is one of the novel antibodies, and it has confirmed the neutralizing ability of the COVID-19 mutation and the potentially resistant virus of Rekkirona'. He said, 'We will enter phase 1 clinical trial within the third quarter of this year'...'We are developing a cocktail treatment of CT-P59·63 or a new antibody for the treatment of patients with vaccine- and treatment-resistant virus infections along with Rekkirona.'"

New P1 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease